Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Korosho Cancels 32% of Flu Vaccine Contracts with GSK
April 12, 2010
- Chuikyo to Discuss Drug Pricing System to Deal with 2010 Problem
April 12, 2010
- Diagnostic Criteria for Diabetes to Switch from JDS to NGSP HbA1c Values: Dr Seino
April 12, 2010
- Medical Need Assessed for Only 1/4 of Unapproved Drugs, Indications Listed
April 12, 2010
- US Healthcare Reform to Benefit Drug Industry: Datamonitor
April 12, 2010
- Astellas Signs CDA with OSI
April 12, 2010
- Healthcare Reform to Expand US Drug Market: Mr Wolf of PhRMA
April 12, 2010
- Exforge to Be Novartis' Next Mainstay Product
April 12, 2010
- Expiration Date of OSI Tender Offer Extended to April 23
April 12, 2010
- Eisai Applies for Eribulin in Japan, US, Europe
April 12, 2010
- Takeda Licenses Ferumoxytol from AMAG
April 12, 2010
- Eisai Creates Oncology Area Department
April 12, 2010
- Banyu Applies for Rotavirus Vaccine
April 12, 2010
- Teijin Pharma Licenses TMX-67 to Astellas in China, Hong Kong
April 12, 2010
- Terumo Creates Diabetes Company Aiming at Top Share
April 12, 2010
- GSK's Revolade Approved for Chronic ITP in Europe
April 12, 2010
- Colon Cancer, Center of Attention in Oncology Market in 2010: Dr Gochenauer of Kantar Health
April 12, 2010
- Korosho to Approve Orphan Drugs Earlier
April 5, 2010
- Reclassification to Be Considered for 7 Class 1 OTC Drugs
April 5, 2010
- Industry Should Be Prepared for Discussions to Perpetuate New Pricing System: Mr Nagano
April 5, 2010
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…